Biarylic precursor compounds for novel ciap inhibitor development
Specialized biarylic scaffold compounds designed as precursors for dual inhibitors of apoptosis proteins (cIAP). These intermediates enable the connection of two pharmacophores, supporting targeted research in apoptosis regulation and potential therapeutic applications in cancer and inflammatory diseases.
Overview
This offering provides access to specialized biarylic compounds developed as precursors for novel cellular inhibitor of apoptosis protein (cIAP) inhibitors. cIAP proteins play a critical role in regulating programmed cell death, and their modulation is a promising strategy in oncology and inflammatory disease research. The biarylic scaffold serves as a central connection element bridging two pharmacophores, enabling the design of dual inhibitors that can simultaneously target multiple binding sites or mechanisms. These compounds are intended for researchers and organizations exploring apoptosis pathways, drug discovery, and the development of targeted therapeutics.
Technical specifications
Key features:
- Biarylic scaffold structure designed to connect two pharmacophores for dual-target inhibition
- Precursor compounds tailored for cIAP inhibitor synthesis
- Applicable to research on inhibitor of apoptosis proteins (IAPs) and apoptosis regulation
- Potential relevance to oncology and inflammatory disease drug discovery programs
- Synthesized using established medicinal chemistry approaches suitable for further derivatization and optimization
Technology readiness level
These compounds are at an early research stage as chemical precursors for cIAP inhibitor development. They have been designed and synthesized based on a scaffold hypothesis but have not yet been validated as functional cIAP inhibitors. Further testing is required to confirm biological activity, binding affinity, and therapeutic potential.
About Heinrich Heine Universität Düsseldorf
Heinrich Heine Universität Düsseldorf is a comprehensive public research university anchored by a major medical faculty and a modern science campus. An integrated university hospital and shared core facilities enable clinical translation and access to specialized instrumentation for joint studies. Companies collaborate through on‑campus spaces, contract research, and tailored partnership models, with quick reach to suppliers and manufacturing across North Rhine‑Westphalia’s Rhine‑Ruhr corridor. Research is supported by competitive funding from the German Research Foundation and federal and state ministries, alongside European Union programs. A dedicated technology transfer office manages IP, licensing, and startup support to accelerate industry uptake.
delivered to your inbox.